Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,395.00-3.35%ETH$2,391.93-3.37%GOLD$4,036.20-0.60%OIL$99.27-0.20%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANTX

AN2 Therapeutics, Inc.

Healthcare · Biotechnology

$3.64

Up+$0.04 (+1.11%)

Updated Oct 23, 2026, 9:06 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
30.14M
P/E ratio
-0.98
Dividend yield
0.00%
52-week range
$1.00 – $7.19
Volume
95.19K
Avg. volume
90.8K

Price performance · ANTX

ANTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

ANTX closed at $3.64 after 21 trading sessions, down 25.56% for the selected period.

Last close
$3.64
Period change
-25.56%
Period low
$3.37
Period high
$5.71
Daily close
View OHLC price history
ANTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$3.57$3.72$3.521$3.6495.19K
Oct 21, 2026$3.58$3.78$3.57$3.60177.37K
Oct 20, 2026$3.38$3.59$3.36$3.56129.74K
Oct 19, 2026$3.39$3.46$3.21$3.37330.87K
Oct 16, 2026$3.60$3.62$3.30$3.38281.73K
Oct 15, 2026$3.50$3.69$3.50$3.60295.94K
Oct 14, 2026$3.55$3.73$3.33$3.54431.03K
Oct 13, 2026$4.30$4.32$3.59$3.60515.05K
Oct 12, 2026$4.41$4.41$4.24$4.30298.47K
Oct 9, 2026$4.65$4.67$4.26$4.40442.13K
Oct 8, 2026$4.77$4.86$4.43$4.68427.83K
Oct 7, 2026$5.02$5.06$4.695$4.85365.25K
Oct 6, 2026$5.39$5.60$5.005$5.07318.22K
Oct 5, 2026$5.69$5.86$5.50$5.61299.95K
Oct 2, 2026$5.64$5.99$5.51$5.71451.33K
Oct 1, 2026$5.29$5.73$5.155$5.62509.44K
Sep 30, 2026$5.07$5.35$5.00$5.32199.2K
Sep 29, 2026$4.99$5.20$4.76$5.09178.84K
Sep 28, 2026$4.89$5.17$4.6701$5.01318.46K
Sep 25, 2026$4.91$4.95$4.71$4.88155.13K
Sep 24, 2026$4.77$5.06$4.72$4.89258.94K

Latest ANTX news

The latest Smart Investors Daily articles mentioning ANTX.

Stock researchCompany · Overview

ANTX research

Overview

Company profile and research snapshot.

Company profile

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.75
Implied upside
—
Analysts
—
ANTX recent ratings
DateFirmRatingTarget
Jul 20, 2026GuggenheimBuy—
May 14, 2026Leerink PartnersOutperform—
May 5, 2025JMP SecuritiesMarket Outperform—
Mar 26, 2025Citizens Capital MarketsMarket Outperform—
Feb 25, 2025Citizens Capital MarketsMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

MENLO PARK, Calif., September 28, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS

Yahoo · Sep 16, 2026

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

MENLO PARK, Calif., September 16, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.

Yahoo · Aug 31, 2026

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By